Pub-2023

Articles

Title
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstrom’s Macroglobulinemia?
Report of Consensus Panel 7 from the 11th International Workshop on Waldenström's Macroglobulinemia on priorities for novel clinical trials
Report of Consensus Panel 6 from the 11th International Workshop on Waldenström’s Macroglobulinemia on Management of Waldenström’s Macroglobulinemia Related Amyloidosis
Report of Consensus Panel 5 from the 11th International Workshop on Waldenström’s Macroglobulinemia on COVID-19 prophylaxis and management
Report of Consensus Panel 4 from the 11th International Workshop on Waldenström’s Macroglobulinemia on diagnostic and response criteria
Report of Consensus Panel 3 from the 11th International Workshop on Waldenström’s Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström’s Macroglobulinemia
Report of Consensus Panel 2 from the 11th International Workshop on Waldenström’s Macroglobulinemia on the management of relapsed or refractory WM patients
Report of Consensus Panel 1 from the 11th International Workshop on Waldenström’s Macroglobulinemia on management of symptomatic, treatment-naïve patients
Highlights of the 11th International Workshop on Waldenstrom’s Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia